No Data
October 29th A-share investment lightning rod︱West Pharmaceutical: Shareholders China National Pharmaceutical Group and Hangzhou Chuanhe plan to jointly reduce their shareholding by no more than 3%.
Observing Defense: Stocks may be subject to other risk warnings.
Hualv Biotech (300970.SZ) released its performance for the first three quarters, with a net loss of 35.0899 million yuan.
Hualv Bio (300970.SZ) released the third quarter report of 2024, with the company's revenue in the first three quarters reaching 7...
Hualu Biotech: Report for the third quarter of 2024
Express News | Hualv Life Science: Shareholder holding more than 5% of the shares Hightech Development Plan to reduce shareholding by no more than 5.36%.
Express News | Hua Lue Biotechnology: Shareholder Gao Tou Development Plan to reduce shareholding by no more than 5.36% of the company's shares
Hualu Biotech: 2024 Semi-Annual Report
No Data
No Data